Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 10/2014

01-10-2014 | Review

Wnt/β-catenin pathway in bone cancers

Authors: Jian Tian, Hongbo He, Guanghua Lei

Published in: Tumor Biology | Issue 10/2014

Login to get access

Abstract

The Wnt signaling pathway regulates some of the crucial aspects of cellular processes. The beta-catenin dependent Wnt signaling (Wnt/β-catenin) pathway controls the expression of key developmental genes, and acts as an intracellular signal transducer. The association of Wnt/β-catenin pathway is often reported with different cancers. In this study, we have reviewed the association of Wnt/β-catenin pathway with bone cancers, focusing on carcinogenesis and therapeutic aspects. Wnt/β-catenin pathway is a highly complex and unique signaling pathway, which has ability to regulate gene expression, cell invasion, migration, proliferation, and differentiation for the initiation and progression of bone cancers, especially osteosarcoma. Association of Wnt/β-catenin pathway with chondrosarcoma, Ewing’s sarcoma and chondroma is also documented. Recently, targeting Wnt/β-catenin pathway has gained significant interests as a potential therapeutic application for the treatment of bone cancers. Small RNA technology to knockdown aberrant Wnt/β-catenin or inhibition of β-catenin expression by natural component has shown promising effects against bone cancers. Advances in understanding the mechanisms of Wnt signaling and new technologies have facilitated the discovery of agents that can target and regulate Wnt/β-catenin signaling pathway, and these may provide a basement for the innovative therapeutic approaches in the treatment of bone cancers.
Literature
1.
2.
3.
Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8:387–98.CrossRefPubMed
4.
Rao TP, Kühl M. An updated overview on Wnt signaling pathways: a prelude for more. Circ Res. 2010;106:1798–806.CrossRefPubMed
5.
Mao J, Wang J, Liu B, Pan W, Farr 3rd GH, Flynn C, et al. Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol Cell. 2001;7:801–9.CrossRefPubMed
6.
Zeng X, Huang H, Tamai K, Zhang X, Harada Y, Yokota C, et al. Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development. 2008;135:367–75.CrossRefPubMed
7.
He X, Semenov M, Tamai K, Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development. 2004;131:1663–77.CrossRefPubMed
8.
Sakanaka C, Sun TQ, Williams LT. New steps in the Wnt/beta-catenin signal transduction pathway. Recent Prog Horm Res. 2000;55:225–36.PubMed
9.
Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11–26.CrossRefPubMed
10.
Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet. 2004;36:417–22.CrossRefPubMed
11.
Marques C, Ferreira JM, Andronescu E, Ficai D, Sonmez M, Ficai A. Multifunctional materials for bone cancer treatment. Int J Nanomedicine. 2014;9:2713–25.PubMedCentralPubMed
12.
Rosenberg AE. Robins and cotran pathologic basis of disease. Bone, joints and soft tissue tumors. 8th ed. Philadelphia: WB Saunders; 2010. p. 1203–56.
13.
14.
15.
Calvert GT, Randall RL, Jones KB, Cannon-Albright L, Lessnick S, Schiffman JD. At-risk populations for osteosarcoma: the syndromes and beyond. Sarcoma. 2012;2012:152382.PubMedCentralPubMed
16.
Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Children’s Oncology Group. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children’s Oncology Group. J Clin Oncol. 2008;26:633–8.CrossRefPubMed
17.
Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–90.CrossRefPubMed
18.
19.
Darouassi Y, Touati MM, Chihani M, Nadour K, Boussouga M, Ammar H, et al. Chondrosarcoma metastasis in the thyroid gland: a case report. J Med Case Rep. 2014;8:157.PubMedCentralCrossRefPubMed
20.
Sridhar H, Vijaya M, Clement W, Srinivas C. Chondrosarcoma arising in an enchondroma of the metacarpal bone—a case report. J Clin Diagn Res. 2014;8:142–3.PubMedCentralPubMed
21.
Lin PP, Moussallem CD, Deavers MT. Secondary chondrosarcoma. J Am Acad Orthop Surg. 2010;18:608–15.PubMed
22.
Geng S, Zhang J, Zhang LW, Wu Z, Jia G, Xiao X, et al. Diagnosis and microsurgical treatment of chondromas and chondrosarcomas of the cranial base. Oncol Lett. 2014;8:301–4.PubMedCentralPubMed
23.
Fiorenza F, Abudu A, Grimer RJ, Carter SR, Tillman RM, Ayoub K, et al. Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg (Br). 2002;84:93–9.CrossRef
24.
Chen B, Yang Y, Chen L, Zhou F, Yang H. Unilateral lateral mass fixation of cervical spinal low-grade chondrosarcoma with intralesional resection: a case report. Oncol Lett. 2014;7:1515–8.PubMedCentralPubMed
25.
26.
27.
Cheung MR. Optimization of predictors of Ewing sarcoma cause-specific survival: a population study. Asian Pac J Cancer Prev. 2014;15:4143–5.CrossRefPubMed
28.
Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA, et al. Ewing’s sarcoma family of tumors: current management. Oncologist. 2006;11:503–19.CrossRefPubMed
29.
Owen LA, Kowalewski AA, Lessnick SL. EWS/FLI mediate transcriptional repression via NKX2.2 during oncogenic transformation in Ewing’s sarcoma. PLoS One. 2008;3:e1965.PubMedCentralCrossRefPubMed
30.
31.
Choi Y, Lim WS, Lee AY, Lee SH. Extraskeletal chondroma of the scalp: an atypical location. Indian J Dermatol Venereol Leprol. 2013;79:435–6.CrossRefPubMed
32.
33.
Gungor S, Kamali G, Canat D, Gokdemir G. Soft tissue chondroma of the index finger: clinical, histological and radiological findings in a unique case. Dermatol Online J. 2013;19:18176.PubMed
34.
Rabbani SA, Arakelian A, Farookhi R. LRP5 knockdown: effect on prostate cancer invasion growth and skeletal metastasis in vitro and in vivo. Cancer Med. 2013;2:625–35.PubMedCentralPubMed
35.
Chu T, Teng J, Jiang L, Zhong H, Han B. Lung cancer-derived Dickkopf1 is associated with bone metastasis and the mechanism involves the inhibition of osteoblast differentiation. Biochem Biophys Res Commun. 2014;443:962–8.CrossRefPubMed
36.
Iwaya K, Ogawa H, Kuroda M, Izumi M, Ishida T, Mukai K. Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis. 2003;20:525–9.CrossRefPubMed
37.
Lin CH, Guo Y, Ghaffar S, McQueen P, Pourmorady J, Christ A, et al. Dkk-3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcoma. Sarcoma. 2013;2013:147541.PubMedCentralCrossRefPubMed
38.
Cai Y, Cai T, Chen Y. Wnt pathway in osteosarcoma, from oncogenic to therapeutic. J Cell Biochem. 2014;115:625–31.CrossRefPubMed
39.
Lin CH, Ji T, Chen CF, Hoang BH. Wnt signaling in osteosarcoma. Adv Exp Med Biol. 2014;804:33–45.CrossRefPubMed
40.
Ma Y, Ren Y, Han EQ, Li H, Chen D, Jacobs JJ, et al. Inhibition of the Wnt-β-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy. Biochem Biophys Res Commun. 2013;431:274–9.PubMedCentralCrossRefPubMed
41.
Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M, et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest. 2009;119:837–51.PubMedCentralCrossRefPubMed
42.
Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G, Cleton-Jansen AM. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol. 2010;220:24–33.CrossRefPubMed
43.
Wan Y, Zhao W, Jiang Y, Liu D, Meng G, Cai Y. β-catenin is a valuable marker for differential diagnosis of osteoblastoma and osteosarcoma. Hum Pathol. 2014;45:1459–65.CrossRefPubMed
44.
45.
Fanburg-Smith JC, Auerbach A, Marwaha JS, Wang Z, Rushing EJ. Reappraisal of mesenchymal chondrosarcoma: novel morphologic observations of the hyaline cartilage and endochondral ossification and beta-catenin, Sox9, and osteocalcin immunostaining of 22 cases. Hum Pathol. 2010;41:653–62.CrossRefPubMed
46.
Uren A, Wolf V, Sun YF, Azari A, Rubin JS, Toretsky JA. Wnt/Frizzled signaling in Ewing sarcoma. Pediatr Blood Cancer. 2004;43:243–9.CrossRefPubMed
47.
Endo Y, Beauchamp E, Woods D, Taylor WG, Toretsky JA, Uren A, et al. Wnt-3a and Dickkopf-1 stimulate neurite outgrowth in Ewing tumor cells via a Frizzled3- and c-Jun N-terminal kinase-dependent mechanism. Mol Cell Biol. 2008;28:2368–79.PubMedCentralCrossRefPubMed
48.
Hill TP, Später D, Taketo MM, Birchmeier W, Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell. 2005;8:727–38.CrossRefPubMed
49.
Yuasa T, Kondo N, Yasuhara R, Shimono K, Mackem S, Pacifici M, et al. Transient activation of Wnt/{beta}-catenin signaling induces abnormal growth plate closure and articular cartilage thickening in postnatal mice. Am J Pathol. 2009;175:1993–2003.PubMedCentralCrossRefPubMed
50.
Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell. 2005;8:739–50.CrossRefPubMed
51.
Cantley L, Saunders C, Guttenberg M, Candela ME, Ohta Y, Yasuhara R, et al. Loss of β-catenin induces multifocal periosteal chondroma-like masses in mice. Am J Pathol. 2013;182:917–27.PubMedCentralCrossRefPubMed
52.
Richardson RB. Age-specific bone tumour incidence rates are governed by stem cell exhaustion influencing the supply and demand of progenitor cells. Mech Ageing Dev. 2014;139C:31–40.CrossRef
53.
Jin S, Shen JN, Wang J, Huang G, Zhou JG. Oridonin induced apoptosis through Akt and MAPKs signaling pathways in human osteosarcoma cells. Cancer Biol Ther. 2007;6:261–8.CrossRefPubMed
54.
Liu Y, Liu YZ, Zhang RX, Wang X, Meng ZJ, Huang J, et al. Oridonin inhibits the proliferation of human osteosarcoma cells by suppressing Wnt/β-catenin signaling. Int J Oncol. 2014;45:795–803.PubMed
55.
Zhang F, Chen A, Chen J, Yu T, Guo F. SiRNA-mediated silencing of beta-catenin suppresses invasion and chemosensitivity to doxorubicin in MG-63 osteosarcoma cells. Asian Pac J Cancer Prev. 2011;12:239–45.PubMed
56.
Xia JJ, Pei LB, Zhuang JP, Ji Y, Xu GP, Zhang ZP, et al. Celecoxib inhibits β-catenin-dependent survival of the human osteosarcoma MG-63 cell line. J Int Med Res. 2010;38:1294–304.CrossRefPubMed
57.
Leow PC, Tian Q, Ong ZY, Yang Z, Ee PL. Antitumor activity of natural compounds, curcumin and p KF118–310, as Wnt/β-catenin antagonists against human osteosarcoma cells. Investig New Drugs. 2010;28:766–82.CrossRef
58.
Leow PC, Bahety P, Boon CP, Lee CY, Tan KL, Yang T, et al. Functionalized curcumin analogs as potent modulators of the Wnt/β-catenin signaling pathway. Eur J Med Chem. 2014;71:67–80.CrossRefPubMed
59.
Liu Y, Wang W, Xu J, Li L, Dong Q, Shi Q, et al. Dihydroartemisinin inhibits tumor growth of human osteosarcoma cells by suppressing Wnt/β-catenin signaling. Oncol Rep. 2013;30:1723–30.PubMed
60.
Zeng L, Wang W, Rong XF, Zhong Y, Jia P, Zhou GQ, et al. Chondroprotective effects and multi-target mechanisms of Icariin in IL-1 beta-induced human SW 1353 chondrosarcoma cells and a rat osteoarthritis model. Int Immunopharmacol. 2014;18:175–81.CrossRefPubMed
61.
Fuerer C, Habib SJ, Nusse R. A study on the interactions between heparin sulfate proteoglycans and Wnt proteins. Dev Dyn. 2010;239:184–90.PubMedCentralPubMed
Metadata
Title
Wnt/β-catenin pathway in bone cancers
Authors
Jian Tian
Hongbo He
Guanghua Lei
Publication date
01-10-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2433-8

Other articles of this Issue 10/2014

Tumor Biology 10/2014 Go to the issue

Research Article

Phosphorylated p38, a negative prognostic biomarker, complements TNM staging prognostication in colorectal cancer

Research Article

lncRNA-AC130710 targeting by miR-129-5p is upregulated in gastric cancer and associates with poor prognosis

Research Article

Silencing survivin activates autophagy as an alternative survival pathway in HCC cells

Research Article

RETRACTED ARTICLE: Epidermal growth factor induces FoxO1 nuclear exclusion to activate MMP7-mediated metastasis of larynx carcinoma

Research Article

Clinicopathological significance of RUNX3 gene hypermethylation in hepatocellular carcinoma

Research Article

Up-regulation of flotillin-2 is associated with renal cell carcinoma progression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits